文献速递免疫规划卫生政策与健康促进

2009-2015年疫苗不良事件报告系统中四价人乳头瘤病毒疫苗上市后安全性监测

Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.
PubMed 文献 · Vaccine · 2018-02-21

研究基于美国疫苗不良事件报告系统(VAERS),检索2009年1月至2015年12月四价人乳头瘤病毒疫苗(4vHPV)的不良事件报告,共纳入19760份报告,其中94.2%为非严重报告,常见症状为头晕、晕厥和注射部位反应;未发现新的或非预期的安全性问题,4vHPV安全性特征与上市前试验和上市后安全性数据一致。

要点

  • VAERS共收到19760份4vHPV接种后报告,94.2%为非严重报告。
  • 头晕、晕厥和注射部位反应在男性和女性中均常见报告。
  • 未发现新的或非预期的安全性问题或具有临床重要性的不良事件报告模式。

核心结论

  • 未检测到4vHPV新的或非预期的安全性问题或具有临床重要性的不良事件报告模式;其安全性特征与上市前试验和上市后安全性数据一致。

研究设计与样本

  • 研究检索了美国疫苗不良事件报告系统(VAERS)中2009年1月至2015年12月期间接种4vHPV后发生不良事件(AE)的美国报告,并采用MedDRA编码症状与体征,计算报告率并进行经验贝叶斯数据挖掘以识别不成比例报告,临床医生审查了包括病历在内的可用信息及选定的预设条件报告。

主要发现

  • VAERS共收到19760份4vHPV接种后报告,其中女性占60.2%,男性占17.2%,22.6%的报告性别缺失。
  • 总体94.2%的报告为非严重报告;头晕、晕厥和注射部位反应在男性和女性中均常见报告。
  • 头痛、疲劳和恶心是常见的严重不良事件报告。
  • 在29份经核实的死亡报告中,死亡按诊断、合并症、年龄或从接种到死亡的时间间隔均无聚集模式。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Food and Drug Administration (FDA) approved quadrivalent human papillomavirus vaccine (4vHPV) for use in females and males aged 9-26 years, since 2006 and 2009 respectively. We characterized reports to the Vaccine Adverse Event Reporting System (VAERS), a US spontaneous reporting system, in females and males who received 4vHPV vaccination. METHODS: We searched VAERS for US reports of adverse events (AEs) following 4vHPV from January 2009 through December 2015. Signs and symptoms were coded using Medical Dictionary for Regulatory Activities (MedDRA). We calculated reporting rates and conducted empirical Bayesian data mining to identify disproportional reports. Clinicians reviewed available information, including medical records, and reports of selected pre-specified conditions. FINDINGS: VAERS received 19,760 reports following 4vHPV; 60.2% in females, 17.2% in males, and in 22.6% sex was missing. Overall, 94.2% of reports were non-serious; dizziness, syncope and injection site reactions were commonly reported in both males and females. Headache, fatigue and nausea were commonly reported serious AEs. More than 60 million 4vHPV doses were distributed during the study period. Crude AE reporting rates were 327 reports per million 4vHPV doses distributed for all reports, and 19 per million for serious reports. Among 29 verified reports of death, there was no pattern of clustering of deaths by diagnosis, co-morbidities, age, or interval from vaccination to death. INTERPRETATION: No new or unexpected safety concerns or reporting patterns of 4vHPV with clinically important AEs were detected. Safety profile of 4vHPV is consistent with data from pre-licensure trials and postmarketing safety data.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Arana JE, Harrington T, Cano M, et al. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015. Vaccine. 2018. PMID: 29477308. doi:10.1016/j.vaccine.2018.02.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。